SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is under intense pressure as investors express skepticism toward the company's high debt load and recent struggles with operational fundamentals. The community is actively debating whether current price levels present a deep-value buying opportunity or a warning sign of further downside as bearish sentiment among traders continues to mount.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently experiencing high volatility driven by speculation regarding a strategic partnership with Meta-Bounds and potential integration into AR glasses, though investors remain sharply divided over the company's ability to scale manufacturing yields. The stock is seeing significant institutional accumulation and heightened options activity, with the community actively debating whether current price levels represent a bottom-tier entry point or a long-term trap fueled by unconfirmed hype.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing significant after-hours volatility as investors react to the CMS finalizing a Medicare Advantage payment rate increase of 2.48% for 2027, a figure that significantly outperformed initial market expectations. The community is actively debating whether this news acts as a definitive bullish catalyst to spark a short squeeze and long-term recovery or if persistent regulatory headwinds and broader sector uncertainty will continue to pressure the stock.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is gaining attention as a long-standing cultural meme, with the community actively debating whether its 15-year history and satirical roots position it as a legitimate contender to flip established assets. Discussions are centered on its transition to the blockchain and the narrative that its irreverent, "anti-establishment" nature provides a unique form of lasting value in a volatile meme coin market.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is capturing market attention as geopolitical tensions in the Middle East drive crude oil prices higher, fueling expectations for increased demand in offshore drilling. The company's recent merger announcement with Valaris and its robust contract backlog are also central to bullish community sentiment, as investors weigh these strong operational fundamentals against the broader volatility of the energy sector.

Owlet, Inc. is a digital parenting platform, which engages in the provision of real-time data and insights, and parenting solutions. It focuses on developing and marketing its products and content for children. It offers the Owlet BabySat, Owlet OTC Smart Sock, and Owlet Band products that allow the sharing of infant sleep and health data and also provides an end-to-end digital healthcare solution for its customers. It operates through the following geographical segments: Unites States, United Kingdom, and Other. The company was founded by Kurt Workman, Zack Bomsta, Jordan Monroe, and Jacob Colvin in 2012 and is headquartered in Lehi, UT.

Owlet Inc - Ordinary Shares - Class A

Owlet Inc. is seeing intense investor activity following a CEO transition and positive Q4 earnings that highlighted record revenue growth and a shift toward profitability. The community is buzzing over the stock's potential as a long-term value play, with active discussions focused on the company's expanding subscription model, the potential for strategic M&A, and bullish sentiment surrounding its unique position as an FDA-cleared pediatric health platform.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing intense downward pressure following a bearish downgrade from JPMorgan that warns of significant downside potential based on concerns over declining vehicle deliveries and market share. The community is sharply divided, with frustrated bears highlighting the stock's high valuation and missing growth metrics, while vocal bulls are dismissing the analyst note as market manipulation and continuing to buy what they perceive as a discount ahead of future AI and robotics initiatives.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics is attracting significant attention as investors react to its role as a key supplier for U.S. military augmented reality and ballistic optics projects. The stock's volatile price action and tight float have led to intense discussion among market participants regarding potential short-squeeze dynamics and the company's long-term growth prospects within the defense and space sectors.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently a major focus for traders as the community debates its long-term viability versus its recent performance as a lagging asset, with active discussions centering on upcoming regulatory milestones like the Clarity Act and the launch of new spot ETFs. Investors are split between those aggressively averaging down in anticipation of a potential sector-wide rotation into RWA-focused infrastructure and those expressing frustration over the persistent downward price action and lack of volume.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is capturing significant trader attention as a high-performance Layer 1 blockchain, with the community actively discussing its potential to rival established networks like Solana through superior transaction speeds and parallel processing capabilities. Investors are heavily focused on staking rewards as a primary incentive, while sentiment remains deeply polarized between those aggressively accumulating during price volatility and others wary of future token unlocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Artelo Biosciences shares gained more than 23% before the opening bell on Tuesday after the company announced the closure of its $11 million private placement of common stock.</li><li>Bullfrog AI shares soared more than 12% in Tuesday’s pre-market trade, building on the gains of 107% on Monday after the company announced an agreement with a major global pharmaceutical company.</li><li>Hitek Global shares more than doubled in Tuesday’s pre-market trade, soaring 110% as the company’s $3 million registered direct offering of Class A ordinary shares closed on Monday.</li></ul>U.S. equities were in the green in Tuesday’s pre-market trade after President Donald Trump reportedly indicated that he would be willing to end the Iran war without a complete reopening of the Strait of Hormuz.According to a report by The Wall Street Journal, President Trump told his aides about his willingness to end the war without getting Iran to reopen the strait following an assessment that this mission would result in prolonging the conflict beyond the four to six-week timeline.At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was up 0.92%; the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust ETF</a> (QQQ) rose 0.86%; and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) gained 0.94%. Retail sentiment on Stocktwits regarding the S&amp;P 500 ETF was in the ‘extremely bearish’ territory.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Tuesday’s pre-market trade:</h2><a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences Inc. (ARTL)</a>Artelo Biosciences shares gained more than 23% before the opening bell on Tuesday after the company announced the closure of its $11 million private placement of common stock. Artelo stated that it intends to use the proceeds to repay a bridge debt and meet working capital requirements.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 139% year-to-date.<a href="https://stocktwits.com/symbol/BFRG">Bullfrog AI Holdings Inc. (BFRG)</a>Bullfrog AI shares soared more than 12% in Tuesday’s pre-market trade, building on the gains of 107% on Monday after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bfrg-stock-more-than-doubled-today-what-is-fueling-the-surge/cZERFnXRIZz">announced</a> an agreement with a major global pharmaceutical company to accelerate its drug discovery and clinical development programs.<a href="https://stocktwits.com/symbol/BFRG">BFRG stock</a> is up 19% year-to-date.<a href="https://stocktwits.com/symbol/HKIT">Hitek Global Inc. (HKIT)</a>Hitek Global shares more than doubled in Tuesday’s pre-market trade, soaring 110% as the company’s $3 million registered direct offering of Class A ordinary shares closed on Monday.<a href="https://stocktwits.com/symbol/HKIT">HKIT stock</a> is down 98% year to date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jerome-powell-fed-iran-war-effects-not-facing-policy-decision-yet/cZERs6iRIN9">Powell Says Fed ‘Not Really Facing’ Policy Decision Yet Amid Iran Oil Shock – Adds Central Bank Will Be ‘Mindful Of The Broader Context’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ARTL, BFRG, HKIT Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today

U.S. equities gained in Tuesday’s pre-market trade after President Donald Trump reportedly stated that the Iran war could be ended without a full reopening of the Strait of Hormuz.

Equity

Medical Stocks To Research - March 27th

UnitedHealth Group, Artelo Biosciences, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly...

Artelo Biosciences Stock Skyrockets 205%

(RTTNews) - Shares of Artelo Biosciences, Inc. (ARTL) are skyrocketing about 205 percent on Friday morning trading despite no corporate-related announcements to influence the movement...

AI, Biotech, and Biologics Drive Big Narratives

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

Artelo Biosciences Targets GLP-1 Boom with Muscle Preservation Strategy as Stock Eyes Squeeze Potential

Artelo Biosciences (NASDAQ:ARTL) is expanding the development pathway for its lead candidate ART27.13, positioning the compound as a potential companion therapy to GLP-1 weight-loss drugs, one of the fastest-growing segments in biopharma.

<ul><li>Artelo indicated it will defer the planned securities offering for the moment.</li><li>The company confirmed no shares were sold and may consider fundraising later.</li><li>On Thursday, Artelo said it plans to test ART27.13 for preserving muscle in GLP-1 patients.</li></ul>Artelo Biosciences, Inc. (ARTL)&nbsp; has formally requested the withdrawal of its recently effective registration statement for a planned securities offering, signaling a pause in its capital-raising efforts.On Friday, the company submitted a request under Rule 477 of the Securities Act of 1933 to withdraw its Form S-1, initially filed with the U.S. Securities and Exchange Commission on March 20 and declared effective on March 25.<h2 class="st-heading-2">Artelo Pauses Proposed Securities Offering</h2>Artelo stated that it does not plan to move forward with the proposed securities offering at this time.&nbsp;The company emphasized that no shares were issued or sold under the registration statement, and it intends to revisit capital-raising options in the future when conditions are more favorable.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences stock</a> traded over 420% higher on Friday afternoon.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘extremely high’ message volume levels.&nbsp;Additionally, the company announced a new private placement involving the sale of more than 3.18 million shares or equivalent pre-funded warrants. The transaction is expected to finalize around March 30, and the company expects gross proceeds of approximately $11 million.<h2 class="st-heading-2">Strategic Expansion Initiative</h2>On Thursday, Artelo announced plans to explore a new application for its ART27.13 compound. The therapy targets muscle preservation in patients undergoing glucagon-like peptide-1 (GLP-1) receptor agonist treatment to address lean body mass loss.&nbsp;The initiative builds on multiple promising developments. ART27.13 demonstrated protective effects on muscle in the CAReS trial, showing increased lean body mass and enhanced physical activity in cancer anorexia and cachexia patients.Artelo Biosciences is a clinical-stage pharmaceutical company focused on treatments for cancer, pain, dermatologic, and neurological conditions.ARTL stock has gained over 170% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/entergy-meta-ink-agreement-to-fund-new-gas-plants-for-louisiana-ai-data-center/cZ3H5r4RImT">Entergy, Meta Ink Agreement To Fund New Gas Plants For Louisiana AI Data Center</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Artelo Biosciences logo is seen displayed on a smartphone screen.

 Why Did ARTL Stock Skyrocket Over 420% Today? 

Artelo requested withdrawal of its Form S-1, effective March 25, and will not proceed with the planned securities offering.

Small Cap Stocks To Watch Now - March 18th

AltC Acquisition, Direxion Daily MU Bull 2X Shares, and Artelo Biosciences are the three Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of...

Nano-Cap Artelo Biosciences Stock Explodes Glaucoma Study Collaboration Ignites Rally

Artelo Biosciences shares jump after a glaucoma study deal to test ART27.13, a new treatment targeting eye pressure in patients.read more...

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. $ARTL, $TGNT, $AIM, $YYGH

<ul><li>Artelo is developing ART27.13, which is a synthetic drug that targets cannabinoid receptors, but only outside the brain.</li><li>The company said preclinical research suggests that peripheral cannabinoid receptor activity may positively influence aqueous humor dynamics and ocular blood outflow.</li><li>Artelo is developing ART27.13 as a once-daily oral drug that could improve body weight, appetite, muscle degeneration, and overall quality of life in cancer patients.</li></ul>&nbsp;Artelo Biosciences Inc. (ARTL) on Wednesday announced that it has secured a fully funded glaucoma study following an agreement with Glaucoma UK and the HSC R&amp;D Division.The study will evaluate the effects of Artelo’s peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences shares</a> were up more than 33% in Wednesday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory with message volumes at ‘high’ levels at the time of writing.—What Is The ART27.13 Treatment?ART27.13 is a synthetic drug that targets cannabinoid receptors, but only outside the brain. The company stated that preclinical research suggests that peripheral cannabinoid receptor activity may positively influence aqueous humor dynamics and ocular blood outflow. These are the two key mechanisms involved in intraocular pressure regulation.“The ophthalmology community has long recognized the potential of cannabinoids in managing intraocular pressure, but their use has been limited by central nervous system effects. ART27.13’s peripherally selective design may overcome this challenge,” said Artelo CEO Greg D. Gorgas.The company is developing ART27.13 as a once-daily, orally administered drug. Artelo says it has the potential to improve body weight, appetite, muscle degeneration, and quality of life in cancer patients.What Does Artelo Do?Artelo is a California-based clinical-stage pharmaceutical company currently developing and commercializing proprietary therapeutics that modulate how fat-based molecules signal between cells.The company has a diversified pipeline of therapeutics for patients with anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 75% year-to-date, but down 61% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 18% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palladyne-ai-subsidiary-wins-us-navy-contract-for-near-hypersonic-missiles/cZ379ezRIgL">Palladyne AI Subsidiary Wins US Navy Contract For Developing New Missiles — PDYN Stock Soars Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is ARTL Stock Soaring Today?

Artelo Biosciences secured a fully-funded study to evaluate the effects of its peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

Current Price	$6.61
Prev Close	$7.04
Open	$6.83
Dividend Yield	0.00%
50-Day Moving Average	$4.91
Beta	0.53
Avg. Volume	7.72M
PE Ratio	-0.14

52-Week High	$85.80
52-Week Low	$2.96
Market Capitalization	$4.99M
EPS (Annual)	-$37.55
Price to Book	-3.50
Revenue Per Employee	$0.00

ARTL
Artelo Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ARTL News

ARTLArtelo Biosciences Inc